Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 01-12-2018 | Original Article

Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features

Authors: Anna Bläckberg, Bo Nilson, Volkan Özenci, Lars Olaison, Magnus Rasmussen

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2018

Abstract

Knowledge of infective endocarditis (IE) caused by Streptococcus dysgalactiae (SD) is limited. This study aimed to identify the clinical and microbiological features of SD-caused IE and to investigate any possible synergy between penicillin and gentamicin on SD isolates. Cases of IE 2008–2016 due to SD reported to the Swedish Registry of Infective Endocarditis (SRIE) were identified. Isolates were emm typed and synergy between antibiotics was determined in time-kill experiments. Medical records were reviewed and SD-cases were compared to cases of IE due to other pathogens reported to the SRIE. Fifty cases of SD-caused IE were confirmed. emm types stC74a, stG62647, and stG643 were most commonly encountered. The patients had a median age of 74 years (range 38–93) and were significantly older compared to patients with Staphylococcus aureus-caused IE, (65 years (p = 0.003)). The median time to diagnosis from symptom onset was 1 day for patients with SD-caused IE which was less compared to patients with IE due to the other pathogens (2–15 days). Embolization was seen in 46% and the in-hospital mortality was 8%. Etest-based methods did not indicate any synergy between penicillin and gentamicin whereas synergy was noted for four out of nine isolates applying time-kill assays. This is the largest study of SD-caused IE, a condition with an acute onset predominantly affecting elderly people. Synergy between penicillin and gentamicin against some SD isolates was distinguished but the potential benefit of this must be weighed against the risk of aminoglycoside side effects.

Available only for authorised users

Takahashi T, Ubukata K, Watanabe H (2011) Invasive infection caused by Streptococcus dysgalactiae subsp. equisimilis: characteristics of strains and clinical features. J Infect Chemother 17(1):1–10. https://doi.org/10.1007/s10156-010-0084-2 CrossRefPubMed

Tanaka D, Isobe J, Watahiki M, Nagai Y, Katsukawa C, Kawahara R, Endoh M, Okuno R, Kumagai N, Matsumoto M, Morikawa Y, Ikebe T, Watanabe H (2008) Genetic features of clinical isolates of Streptococcus dysgalactiae subsp. equisimilis possessing Lancefield’s group A antigen. J Clin Microbiol 46(4):1526–1529. https://doi.org/10.1128/jcm.02188-07 CrossRefPubMedPubMedCentral

Jensen CS, Dam-Nielsen C, Arpi M (2015) Matrix-assisted laser desorption/ionization-time of flight mass spectrometry identification of large colony beta-hemolytic streptococci containing Lancefield groups A, C, and G. Infect Dis (Lond) 47(8):575–579. https://doi.org/10.3109/23744235.2015.1043940 CrossRef

Brandt CM, Spellerberg B (2009) Human infections due to Streptococcus dysgalactiae subspecies equisimilis. Clin Infect Dis 49(5):766–772. https://doi.org/10.1086/605085 CrossRefPubMed

Jensen A, Kilian M (2012) Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes. J Clin Microbiol 50(1):113–126. https://doi.org/10.1128/jcm.05900-11 CrossRefPubMedPubMedCentral

Trell K, Nilson B, Rasmussen M (2016) Species and emm-type distribution of group C and G streptococci from different sites of isolation. Diagn Microbiol Infect Dis 86(4):467–469. https://doi.org/10.1016/j.diagmicrobio.2016.09.008 CrossRefPubMed

Rantala S, Vahakuopus S, Vuopio-Varkila J, Vuento R, Syrjanen J (2010) Streptococcus dysgalactiae subsp. equisimilis bacteremia, Finland, 1995-2004. Emerg Infect Dis 16(5):843–846. https://doi.org/10.3201/eid1605.080803 CrossRefPubMedPubMedCentral

Rantala S (2014) Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection. Eur J Clin Microbiol Infect Dis 33(8):1303–1310. https://doi.org/10.1007/s10096-014-2092-0 CrossRefPubMed

Oppegaard O, Mylvaganam HSS, Jordal S, Glambek M, Kittang BR (2017) Clinical and molecular characteristics of infective β-hemolytic streptococcal endocarditis. Diagn Microbiol Infect Dis 89(2):135–142CrossRefPubMed

10.

Lother SA, Jassal DS, Lagace-Wiens P, Keynan Y (2017) Emerging group C and group G streptococcal endocarditis: a Canadian perspective. Int J Infect Dis 65:128–132. https://doi.org/10.1016/j.ijid.2017.10.018 CrossRefPubMed

11.

El Rafei A, DeSimone DC, DeSimone CV, Lahr BD, Steckelberg JM, Sohail MR, Wilson WR, Baddour LM (2016) Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes. Infect Dis (Lond) 48(5):373–378. https://doi.org/10.3109/23744235.2015.1129672 CrossRef

12.

Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL (2002) Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med 162(21):2450–2456CrossRefPubMed

13.

Lam K, Bayer AS (1984) In vitro bactericidal synergy of gentamicin combined with penicillin G, vancomycin, or cefotaxime against group G streptococci. Antimicrob Agents Chemother 26(2):260–262CrossRefPubMedPubMedCentral

14.

Berge A, Ekdahl C, Ekspong L, Julander I, Kurland S, Olaison L, Rasmussen M, Snygg Martin U, Westling K (2016) Infective Endocarditis Working Group, Swedish Society of Infectious Diseases, Sweden May 2016. http://infektion.net/wp-content/uploads/2017/05/vardprogram_infektios_endokardit.pdf. Accessed 20 Apr 2018

15.

Sendi P, Ericsson M, Olaison L (2012) Infective endocarditis caused by group B Streptococcus: the role of aminoglycoside-combination. J Infect 64(1):127–129. https://doi.org/10.1016/j.jinf.2011.11.003 CrossRefPubMed

16.

Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 132(15):1435–1486. https://doi.org/10.1161/cir.0000000000000296 CrossRefPubMed

17.

Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79(1):33–45. https://doi.org/10.1038/ki.2010.337 CrossRefPubMed

18.

Laurent G, Carlier MB, Rollman B, Van Hoof F, Tulkens P (1982) Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 31(23):3861–3870CrossRefPubMed

19.

Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL (2015) 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36(44):3075–3128. https://doi.org/10.1093/eurheartj/ehv319 CrossRefPubMed

20.

Smyth EG, Pallett AP, Davidson RN (1988) Group G streptococcal endocarditis: two case reports, a review of the literature and recommendations for treatment. J Infect 16(2):169–176CrossRefPubMed

21.

Bizzini A, Durussel C, Bille J, Greub G, Prod’hom G (2010) Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol 48(5):1549–1554. https://doi.org/10.1128/jcm.01794-09 CrossRefPubMedPubMedCentral

22.

Matuschek E, Brown DF, Kahlmeter G (2014) Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect 20(4):O255–O266. https://doi.org/10.1111/1469-0691.12373 CrossRefPubMed

23.

Rolston KV, LeFrock JL, Schell RF (1982) Activity of nine antimicrobial agents against Lancefield group C and group G streptococci. Antimicrob Agents Chemother 22(5):930–932CrossRefPubMedPubMedCentral

24.

Bayer AS, Lam K (1983) In vitro susceptibility of group G streptococci to ten antimicrobial agents with broad gram-positive spectra. Clin Ther 5(4):391–397PubMed

25.

Pankey GA, Ashcraft DS, Dornelles A (2013) Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagn Microbiol Infect Dis 77(3):220–226. https://doi.org/10.1016/j.diagmicrobio.2013.07.006 CrossRefPubMed

26.

Weinstein AJ, Moellering RC Jr (1975) Studies of cephalothin: aminoglycoside synergism against enterococci. Antimicrob Agents Chemother 7(5):522–529CrossRefPubMedPubMedCentral

27.

Sunnerhagen T, Hammarlund P, Rasmussen M (2015) A case of suspected infective endocarditis with Lactococcus garvieae: lack of in vitro synergy between ampicillin and gentamicin. JMM Case Reports 2 (1). https://doi.org/10.1099/jmmcr.0.000018

28.

Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr., Ryan T, Bashore T, Corey GR (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical infectious diseases 30 (4):633–638. https://doi.org/10.1086/313753 CrossRefPubMed

29.

Oppegaard O, Mylvaganam H, Kittang BR (2015) Beta-haemolytic group A, C and G streptococcal infections in Western Norway: a 15-year retrospective survey. Clin Microbiol Infect 21(2):171–178. https://doi.org/10.1016/j.cmi.2014.08.019 CrossRefPubMed

30.

Lindell F, Söderquist B, Sundman K, Olaison L, Källman J (2018) Prosthetic valve endocarditis caused by Propionibacterium species: a national registry-based study of 51 Swedish cases. Eur J Clin Microbiol Infect Dis 37(4):765–771. https://doi.org/10.1007/s10096-017-3172-8 CrossRefPubMedPubMedCentral

31.

Poulin MF, Boivin G (2009) A case of disseminated infection caused by Streptococcus equi subspecies zooepidemicus. Can J Infect Dis Med Microbiol 20(2):59–61CrossRefPubMedPubMedCentral

32.

Lacave G, Coutard A, Troche G, Augusto S, Pons S, Zuber B, Laurent V, Amara M, Couzon B, Bedos JP, Pangon B, Grimaldi D (2016) Endocarditis caused by Streptococcus canis: an emerging zoonosis? Infection 44(1):111–114. https://doi.org/10.1007/s15010-015-0809-3 CrossRefPubMed

Title: Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features
Authors: Anna Bläckberg
Bo Nilson
Volkan Özenci
Lars Olaison
Magnus Rasmussen
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3367-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2018

Variable spectrum of disease and risk factors of peripartum Clostridium difficile infection: report of 14 cases from French hospitals and literature review

Related carbapenemase-producing Klebsiella isolates detected in both a hospital and associated aquatic environment in Sweden

A comparison of Sensititre™ Anaerobe MIC plate with ATB ANA® test for the routine susceptibility testing of common anaerobe pathogens

Implications of stx loss for clinical diagnostics of Shiga toxin-producing Escherichia coli

Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection

Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page